 |
|
|
| |
Early Viral Kinetics Do Not Predict Treatment Outcome With Sofosbuvir + Ribavirin for 12 or 24 Weeks in HCV Genotype 2/3 Patients in the VALENCE Trial
|
| |
| |
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Stefan Zeuzem,1 Geoffrey M. Dusheiko,2 Massimo Colombo,3 Robert Flisiak,4 Robert H. Hyland,5 Ari Illeperuma,5 Diana M. Brainard,5 William T. Symonds,5
John G. McHutchison,5 Ola Weiland,6 Hendrik W. Reesink,7 Ashley Brown,8 Stanislas Pol,9 Christophe Hezode,10 Rafael Esteban11
1Johann Wolfgang Goethe University, Frankfurt, Germany; 2Royal Free and University College School of Medicine, Royal Free Hospital, London, UK; 3University of Milan, Italy; 4Medical University of Bialystok, Poland; 5Gilead Sciences, Inc., Foster City, California, USA; 6Karolinska Institutet, Karolinska University Hospital Huddinge,
Stockholm, Sweden; 7Academic Medical Center, Amsterdam, the Netherlands; 8Imperial College Healthcare NHS Trust, London; 9Hôpital Cochin, Paris, France; 10Centre Hospitalier Universitaire Henri Mondor de Créteil, France; 11Hospital Universitario Vall d'Hebron, Barcelona, Spain
|
| |
|
|
|
|
|
